Plasmodium knowlesi – an emerging pathogen by Ahmed, M.A. & Cox Singh, Janet
ISBT Science Series (2015) 10 (Suppl. 1), 134–140
REVIEW ARTICLE 2B–PL1–02 © 2015 The AuthorsISBT Science Series published by John Wiley & Sons Ltd
on behalf of International Society of Blood Transfusion
Plasmodium knowlesi – an emerging pathogen
M. A. Ahmed1 & J. Cox-Singh2
1School of Medicine, University of St Andrews, St Andrews, UK
2Department of Parasitology, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Ten years have passed since the publication of a large focus of Plasmodium
knowlesi infections in the human population. The discovery was made during a
molecular investigation of atypical P. malariae cases in the Kapit Health Divi-
sion, Sarawak, Malaysian Borneo. Patients were more symptomatic with higher
parasite counts than expected in P. malariae infections. The investigation found
only P. knowlesi DNA present in patient blood samples. Morphological similarity
had allowed P. knowlesi to masquerade as P. malariae during routine diagnostic
microscopy for malaria. P. knowlesi, a malaria parasite of macaque monkeys,
had entered the human population. The subsequent development of P. knowlesi
species-specific PCR assays soon demonstrated that the entry was not confined to
the Kapit Division but extended across island and mainland Southeast Asia.
Relevant clinical descriptions and guidelines for the treatment and management
of patents with P. knowlesi malaria were not available. Nor was it clear whether
P. knowlesi had undergone a host switch event into the human population or if
infections were zoonotic. The outputs of studies on P. knowlesi malaria during
the past 10 years will be summarized, highlighting major findings within the
context of pathophysiology, virulence, host switch events, treatment, control and
importantly malaria elimination.
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Introduction
Malaria parasites, member species of the genus Plasmo-
dium, are blood-borne and pose a substantial risk in
blood transfusion related infection [1–5]. Donor blood
infected with any of the human-host-adapted Plasmodium
species, P. falciparum, P. vivax, P. ovale and P. malariae
or newly emergent species such as P. knowlesi would
cause malaria in the untreated non-immune recipient.
Most medical texts and guidelines for malaria provide
detailed information on the human–host-adapted malaria
parasites but not on emergent species. P. knowlesi, a par-
asite of the long and pig-tailed macaques of Southeast
Asia, is not vertebrate host restricted, and humans, under
experimental conditions, were permissive to infection [6].
Clinical information collected from therapeutically induced
P. knowlesi infections in patients with tertiary syphilis
provides information on human–parasite interaction using
blood passage of laboratory lines of P. knowlesi [6]. How-
ever, naturally acquired P. knowlesi malaria was not recog-
nized and therefore clinically overlooked, until a large focus
of P. knowlesi was described in the human population in
Sarawak, Malaysian Borneo, in 2004 [7]. P. knowlesi is
morphologically indistinguishable from P. malariae, one of
the more benign human-host-adapted Plasmodium species,
and infections were misdiagnosed until the recent develop-
ment of P. knowlesi-specific PCR-based assays [7–9]. The
use of these assays indicate that zoonotic malaria, caused
by P. knowlesi, is widespread in Southeast Asia and, in
stark contrast to P. malariae, is not benign [10–13].
Plasmodium knowlesi pathophysiology
Serial blood passage of a limited number of experimental
lines of P. knowlesi in neurosyphilis patients, pre-antibi-
otic pyretic treatment in the 1950s, was associated with
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increased parasite virulence [6]. The next account of
P. knowlesi pathophysiology came with the first docu-
mented case of naturally acquired P. knowlesi published
in 1965 [14]. The case was diagnosed retrospectively and,
while the patient was symptomatic, he recovered fully
following treatment and no other cases were confirmed.
In fact, when we published the large focus of P. knowlesi
in patients with single-species P. knowlesi infections in
Kapit, Sarawak, we stated that P. knowlesi caused the
usual symptoms of malaria; all patients responded to
treatment and no deaths were reported [7]. This changed
during a subsequent study when four P. knowlesi deaths
were confirmed retrospectively. Only one of these was
reported as a malaria death, P. falciparum, the others
were attributed to other causes [11]. There was no infor-
mation on severe knowlesi malaria in the literature or
medical texts to guide healthcare professionals towards
correct diagnosis and treatment of these patients.
P. knowlesi malaria was new to the medical field, clini-
cians and other healthcare professionals were unaware
that they were dealing with a newly described virulent
form of malaria that, in practice, was most often misdiag-
nosed as the more benign P. malariae. A prospective clin-
ical study on PCR-confirmed single-species P. knowlesi
infected patients confirmed the need for knowlesi-specific
treatment and management guidelines [12]. In that study
107 patients had P. knowlesi malaria, ten had complica-
tions and two died [12]. Complications included >100 000
parasites/ll blood, acute renal impairment, jaundice,
hypotension, lactate acidosis, acute and late onset respira-
tory distress syndrome. All of these complications are
included in the WHO guidelines for severe falciparum
malaria in the non-immune [15]. Notably in this and subse-
quent studies, severe malaria with coma was not described
in severe P. knowlesi infections [11, 12, 16, 17]. Severe
malarial anaemia was reported in children but not adults
and was not as severe as in the P. falciparum comparator
group [18]. In a recent study, 232 adult patients with PCR-
confirmed single-species P. knowlesi infections were
recruited in Sarawak Malaysian Borneo [19]. Twenty-eight
Table 1 Summary of patients with complicated Plasmodium knowlesi malaria (n = 28)
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(12%) of these had complications and four (17%) patients
died, Table 1. Parasitaemia, total bilirubin, serum creati-
nine and plasma lactate were significantly higher in the
complicated group, Fig. 1. Parasitaemia was not used as a
criterion to score severe disease. The study of P. knowlesi
malaria is relatively new, and markers of severe disease are
preliminary but suggest that patients with parasitaemia
>35 000 parasites/ll, bilirubin > 43 lmol/l, serum creati-
nine >256 lmol/l or platelets <45 000/ll are at risk [12,
19]. P. knowlesi is unusual among the parasites that infect
human and non-human primates because the asexual part
of the life cycle, the erythrocytic cycle associated with clin-
ical signs and symptoms, takes 24 h to complete rather
than 48 and 72 h in other types of malaria. Therefore, para-
sitaemia increases daily in P. knowlesi infections, increased
parasitaemia is associated with disease severity, and while
multiplication rates are probably variant specific and the
number of merozoites produced will need to be factored in,
patients with suspected P. knowlesi infection require
urgent diagnosis and rapid access to optimal treatment.
Virulence
Plasmodium knowlesi isolates collected from human infec-
tions are genetically diverse [7, 9]. Parasitaemia is associ-
ated with disease severity and we asked the question are
some P. knowlesi variants more virulent than others? We
sequenced two P. knowlesi genes responsible for parasite
invasion of erythrocytes and found two genetically distinct
clusters of one of the P. knowlesi genes encoding erythro-
cyte invasion proteins, P. knowlesi normocyte binding pro-
tein xa (Pknbpxa) [19, 21]. We found that 44% and 56% of
patients were infected with Pknbpxa cluster 1 and Pknbpxa
cluster 2, respectively. The clusters contained single nucle-
otide polymorphisms that allowed for differentiation of
haplotype groups with 2 or three alleles among the
P. knowlesi isolates. Analysis of the alleles with the clini-
cal and laboratory variables in the patient cohort found
that patients infected with particular allelic forms of clus-
ter 2 had increased markers of disease severity including
parasitaemia [19]. Not all patients with complications were
p = <0.0001 p = <0.0001
p = <0.0001 p = <0.0001
p = <0.0001 p = <0.0001
Fig. 1 Complicated vs. uncomplicated Plasmodium knowlesi disease groups. Patients with P. knowlesi malaria grouped by uncomplicated disease
[U = Green] and complicated disease [C = Red]. Plasma lactate results from a subset of patients (U = 91, C = 20, n = 111). P values were calculated
using the Mann–Whitney U-test for nonparametric data and the unpaired t-test for normally distributed data (Prism 4 for Macintosh; GraphPad Soft-
ware, Inc. San Diego).
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infected with cluster 2 parasites but there were more
patients than expected with complications in this cluster
(Fig. 2). This suggests that, in nature, some P. knowlesi
variants may be more virulent in the human-host popula-
tion than others. This study was conducted in Sarawak,
Malaysian Borneo, and may explain some of the apparent
differential susceptibility of humans to P. knowlesi infec-
tion in Malaysia and other areas within the region. More
work is required to determine genetic diversity of
P. knowlesi across the Southeast Asian region and associ-
ated parasite virulence.
Host switch events
Plasmodium knowlesi infections occur throughout the
Southeast Asian region. The region is separated by high
mountain ranges and large expanses of water including
the South China Sea, the Sulu Sea and Andaman Sea
[21]. P. knowlesi is a parasite of non-human primates
that do not cross oceans and rural human populations at
risk tend to be local. It seems likely that, following the
primary emergence of P. knowlesi and ancient dispersal
events, P. knowlesi, populations have evolved in local
geographical isolation. Each location reporting human
infections is most likely dealing with different genetic
variants of P. knowlesl [22]. The recent discovery of
P. knowlesi malaria in humans was in Kapit, Malaysian
Borneo, and further study found that naturally acquired
P. knowlesi infections occurred throughout Malaysian
Borneo, Peninsular Malaysia, all geographically distinct
areas, and subsequently in most parts of Southeast Asia
[7, 11, 21, 23]. Therefore, it is important not to extrapo-
late studies on genetic diversity and virulence between
geographically distinct transmission sites.
Even so the multiple entry events recorded across South-
east Asia may have been the result of parasite adaptation to
the human host and clonal expansion but the infections are
not clonal or related to any one index case or location [7].
A study on P. knowlesi isolated from the natural macaque
hosts and human infections in Sarawak did not identify
genetic clustering of parasites to either host, strongly sug-
gesting a zoonotic origin for the infections in Sarawak [9].
However, children in Sabah were infected without any
obvious risk behaviour for acquiring a zoonotic infection,
such as spending time in the forest [23]. Also, and perhaps
most worrying, Anopheles balabacensis is a vector of
P. knowlesi in Sabah [16]. An balabacensis is better known
as a vector of P. falciparum in Sabah and therefore well
placed to channel a host switch event for P. knowlesi from
macaque-to-human to human-to-human malaria transmis-
sion at this location [24, 25]. In Vietnam, another geo-
graphically distant and distinct location, children have
asymptomatic low-level P. knowlesi infections mixed with
P. falciparum and P. vivax [26]. Anopheles dirus is the
main malaria vector in this region of Vietnam and trans-
mits all three parasite species, P. knowlesi, P. falciparum
and P. vivax, concurrently [26, 27]. P. knowlesi warrants
careful observation to pre-empt or at least contain a host
switch event in any number of Southeast Asian locations –
quite a monumental task.
Treatment
Earlier studies reported that P. knowlesi responds well to
currently available antimalarial compounds including
chloroquine [7, 12, 28]. The level of sensitivity supports
an absence of drug selection pressure implying a recent
emergence or zoonotic origin for P. knowlesi. Studies
designed to properly assess clinical and parasitological
responses of P. knowlesi to treatment highlight some
important differences in response. In 2005, inherent me-
floquine resistance of P. knowlesi in experimentally
infected Rhesus macaques was reported [29]. Also,
P. knowlesi isolates from human infections responded
poorly to mefloquine ex vivo [30]. Furthermore, the para-
sitaemia in a patient, who presented with severe
P. knowlesi malaria during a second infection, increased
following mefloquine treatment [31]. Nonetheless, other
patients with uncomplicated P. knowlesi infections
responded to mefloquine treatment [32, 33].
Fig. 2 The number of expected and observed cases of Plasmodium
knowlesi malaria infected with parasites with Plasmodium knowlesi nor-
mocyte binding protein (pknbp) xa cluster 1 or cluster 2 parasites.
Pknbpxa haplotypes were generated for 138 patient isolates in a subset
of 147 patients. In the study, 44% of patients were infected with
Pknbpxa cluster 1 type parasites and 56% with Pknbpxa cluster 2 type
parasites. The patients were then grouped into uncomplicated (UC)
n = 112 and complicated (C) n = 28 groups. The expected (Exp) number
of patients in the UC and C groups was calculated based on the 44:56
ration of cluster 1 to cluster infections and compared to the number
observed (Obs). More patients with complicated disease (C Obs) were
infected with Pknbpxa cluster 2 parasites. Chi-square P = 0048; with
Yates correction P = 008 (http://vassarstats.net/tab 2x2.html).
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Plasmodium knowlesi responds to chloroquine albeit
with a higher IC50 ex vivo [30]. Chloroquine should be
used with caution because in the absence of species-spe-
cific diagnostic tests in most regions, the risk of misdiag-
nosing P. falciparum, mostly chloroquine resistant, as
P. knowlesi would put patients at risk.
The most compelling evidence supports the use of arte-
misinin derivatives either as intravenous artesunate or as
oral combination therapies to treat complicated and
uncomplicated P. knowlesi infections. Patients in Sabah
with severe knowlesi malaria were more likely to survive
when given intravenous artesunate than quinine [28]. In
another study in Sabah patients with all cause, malaria
were given oral artemisinin combination therapy or artesu-
nate IV immediately on diagnosis. Most of the patients had
knowlesi malaria, 39% had severe symptoms and all sur-
vived [16]. Both studies report shorter parasite clearance
times for the artemisinin based therapies than chloroquine
or quinine. Also P. knowlesi responded better to artemisi-
nin derivatives than all other compounds ex vivo [30]. In
other studies, IV artesunate performed better than quinine
in treating severe falciparum malaria [34]. It should be
noted that patients with P. knowlesi infections can be
symptomatic at low parasitaemia, lower than the sensitivity
of thick film microscopy [12]. Currently, there is no specific
or sensitive diagnostic test for P. knowlesi malaria [35].
Control of zoonotic malaria
Human cases of P. knowlesi malaria occur across South-
east Asia [10]. This region is known for human, animal,
plant, insect, geographical and geological diversity [36].
Apart from parts of Malaysia and Vietnam, there is little
information on P. knowlesi transmission, reservoirs of
infection, vectors and risk of human infection [27, 37,
38]. Without this information, it will be difficult to design
control measures for zoonotic P. knowlesi acquired in the
jungle setting, over and beyond use of prophylaxis when
spending time in areas where other patients with
P. knowlesi have been infected. The pragmatic solution
would be to encourage location-specific vector, parasite
and natural host monitoring and surveillance. These mea-
sures are currently costly, require manpower and are
logistically difficult. Perhaps a meeting of minds is
required to develop alternative sampling and monitoring
methods for forest settings that would capture the
required data on parasite prevalence, vector capacity, nat-
ural hosts but using minimal manpower. Not an easy
problem to solve on the backdrop of competing public
health problems at each location. In areas where
P. knowlesi is transmitted in human settlements or even
human-to-human, existing malaria control measures
would be expected to be effective.
Malaria elimination
According to the World Health Organization ‘Malaria
elimination is the interruption of local mosquito-borne
malaria transmission, i.e. the reduction to zero of the
incidence of malaria infection in a defined geographical
area.’ [39]. Malaysia has an excellent record in malaria
control; however, Malaysia and other countries in South-
east Asia, pursuing malaria elimination, need to carefully
consider P. knowlesi. There is some evidence that
P. knowlesi enters human populations where national
human-host-adapted, malaria control initiatives are suc-
cessful, a good example of this is Malaysia [13, 40]. This
poses two questions: (i) Will removal of the human-host-
adapted species open a new host niche for P. knowlesi?
or (ii) By removing human host challenge, particularly
with P. vivax, are humans more susceptible to P. knowlesi
through loss of cross protection?
Both scenarios are worth taking seriously. The rela-
tively large number of P. knowlesi cases was discovered
in Malaysia [7]. The study was prompted by the report of
atypical cases of P. malariae in the area. It is possible
that these cases were more visible as cases of P. falcipa-
rum and P. vivax were controlled. Or were there more of
these cases as immunity to malaria declined along with
P. vivax and P. falciparum? Returning to P. knowlesi
induced pyretic therapy in tertiary syphilis. Patients who
were previously treated with P. vivax were partially resis-
tant to subsequent P. knowlesi infection suggesting a
degree cross immunity [6].
There is some debate about the prevalence of zoonotic
malaria – Is P. knowlesi being better recognized because
of heightened awareness and PCR identification? If so,
then the prevalence of P. knowlesi may not have
increased, we are simply looking harder, difficult to argue
against. However, the number of cases of P. knowlesi in
Sabah do seem to be increasing [13]. Regardless, aware-
ness brings the opportunity to deal with a large entry and
host switch events that might threaten malaria elimina-
tion in the area.
If the ultimate goal is malaria eradication, the WHO
definition is much more specific ‘Malaria eradication is
defined as the permanent reduction to zero of the world-
wide incidence of malaria infection caused by a particular
malaria parasite species.’ [39]. If eradication is the goal,
then it would be possible to eradicate P. falciparum,
P. vivax, P. malariae and P. ovale while still tolerating
P. knowlesi in Southeast Asia.
Summary
Plasmodium knowlesi has entered the human population
in Southeast Asia. People who spend time the sylvan
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transmission sites are at risk. P. knowlesi remains largely
zoonotic, but transmission near human settlements is sus-
pected in Sabah. P. knowlesi is diverse and causes severe
disease in at least 10% of those infected in Sabah and
Sarawak. Patients with severe and fatal P. knowlesi infec-
tions fulfil the WHO criteria for severe falciparum malaria
but without coma or severe adult anaemia. Healthcare
professionals should suspect P. knowlesi in patients and
blood donors with a history of time spent in the jungles
of Southeast Asia. Blood donor screening protocols, to
detect malaria exposure, use recombinant P. falciparum
and P. vivax antigen. While there may be some cross
reactivity between P. knowlesi and the phylogenetically
related P. vivax, these reagents could not be used reliably
to detect antibodies to P. knowlesi. At the moment, the
risk of donor blood infection with P. knowlesi would be
expected to be low; however, a history of time spent in
the jungles of Southeast Asia may warrant donor referral
for a 1-year period.
Importantly, evidence suggests that rapid diagnosis and
immediate treatment with artemisinin derivatives is
appropriate for this potentially virulent parasite with a
short erythrocytic life cycle.
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